Methods of therapy and diagnosis using immunotargeting of CD84Hy1-expressing cells
AssigneeNuvelo, Inc.
InventorsDouglas Dedera, Jian-Rui Wang, Peter C. R. Emtage
Life of this patent
Estimating the term…
Abstract
Certain cells, including types of cancer cells such as lymphomas, are capable of expressing high levels of CD84Hy1. Immunotargeting using CD84Hy1 polypeptides, nucleic acids encoding for CD84Hy1 polypeptides and anti-CD84Hy1 antibodies provides a method of killing or inhibiting that growth of CD84HY1Protein-expressing cancer cells. Methods of immunotherapy and diagnosis of disorders associated with CD84Hy1protein-expressing cells are described.
Claims3
An in vitro method of killing or inhibiting the growth of CD84Hy1-expressing cells that cause a disease selected from the group consisting of acute myelogenous leukemia, acute myelomonocytic leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, B cell large cell lymphoma, malignant lymphoma, lymphosarcoma cell leukemia, B-cell lymphoma, T-cell lymphoma, acute myeloid leukemia, Hodgkin's disease, autoimmune disorders, and rejection of transplanted tissues or organs, comprising the step of administering a composition to said cells in an amount effective to kill or inhibit the growth of said cells, wherein said composition is an anti-CD84Hy1 antibody that binds to a polypeptide consisting of the amino acid sequence of SEQ ID NO:
- 2 or amino acid 22 to amino acid 214 of SEQ ID NO:
- 2.
Dependencies are inferred from the claim text.